EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
about
Biomarkers and Targeted Therapy in Pancreatic CancerKRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer.Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?Anti-pancreatic cancer deliverables from sea: first-hand evidence on the efficacy, molecular targets and mode of action for multifarious polyphenols from five different brown-algaePower-Law Modeling of Cancer Cell Fates Driven by Signaling Data to Reveal Drug EffectsK-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis.Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward.Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.Pancreatic biomarkers: could they be the answer?Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts.pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104Smarter drugs emerging in pancreatic cancer therapy.Genetic and molecular alterations in pancreatic cancer: implications for personalized medicine.hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma.New targeted therapies in pancreatic cancer.Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysisProlonged complete response following gemcitabine-erlotinib combined therapy in advanced pancreatic cancerCytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancerStudy of Clinical Survival and Gene Expression in a Sample of Pancreatic Ductal Adenocarcinoma by Parsimony Phylogenetic Analysis.Recombinant adenovirus-p53 (Gendicine) sensitizes a pancreatic carcinoma cell line to radiation.Drug metabolism and pancreatic cancer.Genetic Interactions of STAT3 and Anticancer Drug Development.ALK expression is absent in pancreatic ductal adenocarcinoma.The need for effective pancreatic cancer detection and management: a biomarker-based strategy.Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer.Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitors.Prognostic significance of epidermal growth factor receptor overexpression in pancreas cancer and nodal metastasis.Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer.Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?[Will molecular diagnostics become established in pancreatic pathology?].
P2860
Q26752755-B9CA3840-3062-4061-90ED-0D64D47E48ADQ27852101-7E02501A-46F6-4D37-972C-A23FB772844BQ28066268-81D41709-2ECD-4A20-ADFC-AFDDEA0C9593Q28486199-3A4F1362-FE76-4726-AD60-173CFF6AC2F4Q28552821-28B6D578-D62B-4153-8777-2B437F050CEAQ30250097-3AFEA62E-6ADC-46B7-A2F5-2150A10D818CQ33624574-8A952FB9-FFB0-49C6-A5AA-38AD18B6F2F5Q33730022-17BD4390-2A2A-469E-A67D-3551085F9A3DQ33801371-68C15A6B-8367-4E11-A525-FDF81BBC7EDFQ34067863-6C134BDD-0D2C-441E-B025-D7EADE3046B7Q34123654-27C93FEF-923B-4F1C-B769-90070D796797Q34410212-2E48020C-98D8-4487-9C5B-B36D0AEA9775Q34657038-A7C73CA3-3273-43E6-9495-A4D0D5D16D08Q35198312-89056954-4803-470A-B79C-E823822F8C3BQ35651453-F10C0034-1C80-42FC-A611-8C47AB1F076DQ36018926-41D58096-D827-4356-AF1F-60A1D52C8FEAQ36524171-11FAC442-51F4-4C17-95A5-F68C301341D3Q36889709-CBAD646F-0C13-4E8F-9550-CDCD1DD7B6B8Q37141896-DA336BA5-B723-4D04-A038-379696AD16F0Q37413649-23A1D8DB-3078-4DFB-A03E-B747E08B3188Q37542844-E269444E-F5CD-4153-8BD1-AC6E281D4D63Q38198930-3836D696-FEFC-4707-A564-DD734E8FACB0Q38390927-E1E8F433-7333-48A6-9548-7808C540AC02Q38591066-EDA7C27D-DAE0-4942-B709-7B6401B1DD75Q39204274-259D4F14-4A87-4769-A33A-682FB50F48AFQ40225193-37EB86DA-7B56-4898-8AF2-AE872665CC75Q40332952-6EDD0EE7-41A4-493F-87F4-667611564950Q41289945-9C8FA122-F745-45CB-B985-E249930C1572Q43872838-2F07B306-A933-4961-B01E-384318A5D9FFQ49576059-03E6D09D-7B6D-4992-A19A-3B0599E2814FQ52739894-70EEB63F-B967-4BA8-9C9D-A82CD671596BQ54397309-8B1D4DCB-B316-483E-A0DA-8DEBB1CA165C
P2860
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
EGFR pathway biomarkers in erl ...... over phase 3 trial AIO-PK0104.
@ast
EGFR pathway biomarkers in erl ...... over phase 3 trial AIO-PK0104.
@en
type
label
EGFR pathway biomarkers in erl ...... over phase 3 trial AIO-PK0104.
@ast
EGFR pathway biomarkers in erl ...... over phase 3 trial AIO-PK0104.
@en
prefLabel
EGFR pathway biomarkers in erl ...... over phase 3 trial AIO-PK0104.
@ast
EGFR pathway biomarkers in erl ...... over phase 3 trial AIO-PK0104.
@en
P2093
P2860
P356
P1476
EGFR pathway biomarkers in erl ...... over phase 3 trial AIO-PK0104.
@en
P2093
C Goritschan
C Winkelmann
G Kojouharoff
L Fischer von Weikersthal
M Geissler
M R Clemens
P2860
P2888
P304
P356
10.1038/BJC.2012.495
P407
P577
2012-11-20T00:00:00Z